What is the 13F Pro Quality Score for XENE?

13F Pro ranks Xenon Pharmaceuticals Inc. (XENE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XENE's current score at https://13fpro.ai/research/XENE (free sign-up required for the full ranking).

Which hedge funds own the most XENE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XENE include FMR, Avoro Capital Advisors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/XENE as soon as new 13F filings post.

Where does 13F Pro source XENE data?

All Xenon Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Xenon Pharmaceuticals Inc. files with the SEC under CIK 1582313. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XENE in?

Xenon Pharmaceuticals Inc. (XENE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XENE research updated on 13F Pro?

XENE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xenon Pharmaceuticals Inc.(XENE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1582313 XENE stock profile & AI dashboard →

13F Pro Quality Score

12.9/100

Rank #2,775 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

1.0/100

Balance Sheet

2.9/100

Earnings Quality

30.0/100

Free Cash Flow

0.9/100

Institutional Flow

82.6/100

Revenue Scale

3.0/100

Dilution Risk

0.8/100

XENE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xenon Pharmaceuticals Inc. (XENE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XENE at 12.9/100 on a 32-signal composite quality model, placing it at rank #2,775 of 2,879 stocks — the bottom half of the AI-ranked universe. XENE scores in the top quartile across institutional flow (82.6). Areas of concern include free cash flow (0.9) and profitability (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Xenon Pharmaceuticals Inc. reports net income of $-102.3M, free cash flow of $-89.0M. Top institutional holders of XENE by reported 13-F value include FMR, Avoro Capital Advisors, BlackRock,, based on the most recent SEC filings. XENE trades on the Nasdaq exchange and files with the SEC under CIK 1582313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XENE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xenon Pharmaceuticals Inc. directly from SEC EDGAR. Xenon Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 8 and 35 since 2021, currently 12.9 — a declining long-term trajectory across 40 quarterly and live scoring snapshots.

✦

Fun facts about Xenon Pharmaceuticals Inc.

Quirks, history, and lore behind XENE — the kind of stuff that makes a stock memorable.

1
The Basics
Canadian clinical-stage biopharmaceutical company · listed on Nasdaq · focused on developing drugs that target ion channels in the nervous system.
2
The Numbers
A small-cap biotech with minimal product revenue — the company is largely funded by partnership deals and milestone payments from larger pharma collaborators.
3
The History
Founded in the early 2000s in British Columbia, it built its pipeline around the idea that selectively blocking specific sodium channels could treat pain without the addiction risk of opioids.
4
The Secret
Its crown-jewel programs target Nav1.7 and Nav1.8 sodium channel subtypes — the kind of hyper-specific science that makes neurologists excited and everyone else's eyes glaze over.
5
The Lore
The company struck a major collaboration with Neurocrine Biosciences to co-develop its lead epilepsy and pain candidates, bringing in hundreds of millions in potential milestone payments.
6
The Giveaway
Its name is literally a noble gas — atomic number 54 — attached to the word Pharmaceuticals, traded under a ticker that is basically the element's chemical symbol plus an E.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-102.3M

Free Cash Flow

Q1 2026

$-89.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$7.5MFY 2025

FY22 $9.4MFY23 $0.00FY24 $0.00FY25 $7.5M

Net Income

-47.6% YoY

$-345.9MFY 2025

FY22 $-125.4MFY23 $-182.4MFY24 $-234.3MFY25 $-345.9M

Operating Income

-33.6% YoY

$-373.1MFY 2025

FY22 $-129.1MFY23 $-214.1MFY24 $-279.3MFY25 $-373.1M

EPS (Diluted)

-44.9% YoY

$-4.36FY 2025

FY22 $-2.06FY23 $-2.73FY24 $-3.01FY25 $-4.36

Total Assets

-20.7% YoY

$633.2MFY 2025

FY22 $754.1MFY23 $964.8MFY24 $798.1MFY25 $633.2M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-53.9% YoY

$-279.1MFY 2025

FY22 $-101.0MFY23 $-151.1MFY24 $-181.4MFY25 $-279.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$7.5M	$0.00	$0.00 -100.0%	$9.4M -70.7%	$32.2M +371.0%	$6.8M
Net Income	$-345.9M -47.6%	$-234.3M -28.5%	$-182.4M -45.5%	$-125.4M -334.8%	$-28.8M +30.7%	$-41.6M
Operating Income	$-373.1M -33.6%	$-279.3M -30.5%	$-214.1M -65.7%	$-129.1M -312.6%	$-31.3M +26.9%	$-42.8M
EPS (Diluted)	$-4.36 -44.9%	$-3.01 -10.3%	$-2.73 -32.5%	$-2.06 -154.3%	$-0.81	—
Total Assets	$633.2M -20.7%	$798.1M -17.3%	$964.8M +27.9%	$754.1M +298.6%	$189.2M +28.1%	$147.7M
Total Debt	—	—	—	—	—	$15.5M
Operating Cash Flow	$-279.1M -53.9%	$-181.4M -20.0%	$-151.1M -49.6%	$-101.0M -109.9%	$-48.1M -920.9%	$-4.7M

AI Insight: XENE Financial Trends

Xenon's equity surged to $1.3B in Q1 2026 after collapsing through 2025, signaling a major capital raise amid accelerating cash burn.

• Operating cash flow deteriorated from -$34M (Q2 2024) to -$89M (Q1 2026), a 162% increase in quarterly burn.

• Net loss widened from -$58M (Q2 2024) to -$102M (Q1 2026), with cumulative nine-quarter loss exceeding $730M.

• Equity jumped from $560M (Q3 2025) to $1,338M (Q1 2026), indicating substantial dilutive financing to extend runway.

⚠ Q1 2026 operating loss of -$112M is the highest quarterly deficit on record; revenue remains near zero.

⚠ Despite $1.3B equity cushion, current burn rate (~$90M/quarter cash) implies 14-15 quarters of runway before next raise needed.

AI Insight: XENE Ratio Trends

XENE suffered severe profitability collapse through Q4 2025, with ROIC plunging to -75.5%, but bounced sharply in Q1 2026 to -33.6%—magnitude of swings suggests operational instability.

• ROIC deteriorated from -32.8% in Q2 2024 to nadir of -75.5% in Q4 2025, then recovered 42pp to -33.6% in Q1 2026.

• ROE and ROA followed identical collapse-and-recovery pattern: Q4 2025 hit -72.4% and -66.5% respectively, rebounding to -30.6% and -29.5% in Q1 2026.

⚠ Extreme quarter-to-quarter volatility in return metrics suggests either major one-time charges, revenue/earnings swings, or seasonal working-capital shifts—stability critical.

⚠ Q1 2026 improvement substantial, but still deeply negative across all returns; must confirm if rebound is durable or transient noise.

Get alerted when XENE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xenon Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XENE

FMR LLC
$629.1M10,818,491 sh
Avoro Capital Advisors LLC
$336.0M5,777,777 sh
BlackRock, Inc.
$328.0M5,640,118 sh
WELLINGTON MANAGEMENT GROUP LLP
$280.8M4,829,641 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$261.2M4,491,653 sh
Polar Capital Holdings Plc
$256.2M4,405,312 sh
JANUS HENDERSON GROUP PLC
$242.9M4,175,982 sh
Capital International Investors
$155.5M2,674,727 sh
CITADEL ADVISORS LLC
$154.3M2,652,990 sh
STATE STREET CORP
$100.0M1,720,533 sh

Fund	Value	Shares
FMR LLC	$629.1M	10,818,491
Avoro Capital Advisors LLC	$336.0M	5,777,777
BlackRock, Inc.	$328.0M	5,640,118
WELLINGTON MANAGEMENT GROUP LLP	$280.8M	4,829,641
DRIEHAUS CAPITAL MANAGEMENT LLC	$261.2M	4,491,653
Polar Capital Holdings Plc	$256.2M	4,405,312
JANUS HENDERSON GROUP PLC	$242.9M	4,175,982
Capital International Investors	$155.5M	2,674,727
CITADEL ADVISORS LLC	$154.3M	2,652,990
STATE STREET CORP	$100.0M	1,720,533

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XENE on your watchlist

Track score changes the day Xenon Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XENE a good stock to buy?

13F Pro's AI-powered analysis of Xenon Pharmaceuticals Inc. (XENE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XENE are available on the XENE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XENE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XENE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xenon Pharmaceuticals Inc.'s investment landscape.